Wellington Management, an investment management company, led a $115m Series B funding round in MBX Biosciences, a developer of pre-clinical biotechnology drugs, with participation from RA Capital Management, Norwest Venture Partners, Frazier Life Sciences, New Enterprise Associates and OrbiMed. “MBX has grown tremendously as a company since closing our Series A two years ago, including bringing our lead program MBX 2109 into the clinic, achieving proof of mechanism and now starting the multiple ascending dose portion of our Phase 1 trial. With the support of these leading healthcare investors, we look forward to further advancing our Precision Endocrine Peptides as part of our goal to improve outcomes and quality of life for patients with endocrine disorders," Kent Hawryluk, MBX Biosciences President and CEO.